Background. There are few data on risk factors, chosen therapy and healthcare utilization among US children with extended spectrum β lactamase-positive urinary tract infection (ESBL UTI). We performed a multicenter case-control study on childhood ESBL UTI from November 2014 to February 2017; herein we present preliminary data from a single Los Angeles County hospital.
Background. Long-term acute care Hospital (LTACH) systematically selects a unique patient population with multiple risk factors for Carbapenem-resistant Enterobacteriaceae (CRE) colonization and infection leading to an increase CRE prevalence at these facilities. This selection bias creates a fertile ground to harness scientific data and test hypothesis. We performed a retrospective analysis of patients with CRE infections diagnosed and treated in one LTACH.
Methods. Baseline data, antimicrobial treatment, and outcomes were collected in patients with bacteremia, healthcare-associated pneumonia (HCAP), and complicated urinary tract infection (cUTI)/acute pyelonephritis (AP) due to CRE diagnosed between January 2017 and December 2017.
Results. 57 cases of CRE infections were identified over the study period; 12 bacteremia, 20 HCAP and 25 cUTI/AP. The proportion of patient with significant comorbidities include; 31.5% diabetes, 40.4% heart failure, 29.8% kidney disease and 10% with solid tumors. 89.5% of patients presented with sepsis and 33.3% had septic shock. Among 57 patients, majority (56) received empiric antibiotics known to have activity against Gram negative but only 38.6% had in vitro activity against the CRE organism recovered from cultured specimen. 85% of index CRE isolate was Klebsiella pneumoniae, 8.7% Enterobacter cloacae, 3.5% Proteus mirabilis, and 1.8% Escherichia coli. Treatment regimen varied; however, 78.9% received monotherapy. Overall outcome was poor with 28-day mortality of 17.5% across all infection sites but up to 25% in patients with bacteremia.
Conclusion. In this study, we report our clinical experience treating CRE infections in LTACH. We proved that CRE infections occurred in patients with substantial co-morbidities. Even though clinical outcome remain of great concern, 28-day mortality and rate of eradication of CRE in the study were comparatively better than other national estimates. Inappropriate empiric treatment may be one of the many factors leading to overall poor treatment outcomes.
Disclosures. Methods. This was a single-center, retrospective chart review from January 2006 to September 2017. Subjects were selected by cross-referencing pharmacy billing and culture data. Patients ≥18 years of age were included if they had isolated S. maltophilia in at least one culture and were treated for at least five days. Patients were excluded due to pregnancy, incarceration, cystic fibrosis, receipt of combination therapy, or having prior case of treated S. maltophilia infection. Complete success was defined as meeting all three of the following: (1) resolution of signs/symptoms, (2) no repeat isolation 30 days after end of therapy, and (3) no switch or addition of alternative agents that cover S. maltophilia. Partial success was defined as meeting at least two out of the three criteria.
Results. A total of 109 patients were included in this study. No statistically significant difference in complete clinical success achievement was identified: TMP-SMX 14/32 (43.8%) vs. minocycline 17/37 (45.9%) vs. moxifloxacin 16/40 (40%), P = 0.8674. There was also no significant difference when including those that achieved partial clinical success: TMP-SMX 29/32 (90.6%) vs. minocycline 35/37 (94.6%) vs. moxifloxacin 34/40 (85%), P = 0.3724. Moxifloxacin use was associated with a significantly longer median LOS of 41.5 days compared with 24.5 days for TMP-SMX and 10 days for minocycline (P = 0.0340). Resistance development within 30 days post-treatment only occurred in 4 patients who received moxifloxacin (P = 0.0258). There was no difference in mortality nor treatment duration.
Conclusion. Clinical success achievement was found to be similar in patients treated with TMP-SMX, minocycline, or moxifloxacin monotherapy for S. maltophilia infections.
Disclosures. All Authors: No reported disclosures. Methods. Retrospective review of patients with carbapenem-resistant (CRE) or extended spectrum β-lactamase producing (ESBL) Enterobacteriaceae, or vancomycin-resistant Enterococcus (VRE) UTIs who received ≥1 dose of FOS. UTI was defined as a urine culture with ≥1000 CFU/mL among patients with dysuria, increased urinary frequency, suprapubic or flank pain or tenderness, fevers, or altered mental status without an alternative etiology. We defined cure as resolution of symptoms within 7 days without reoccurrence within 30 days. Microbiological failure was defined as a positive urine culture within 14 days.
A Real-World Perspective on the Efficacy of Fosfomycin for Treatment of Multidrug-Resistant Pathogens Causing Urinary Tract Infections
Results. 49 patients with MDR UTIs (17 ESBL, 17 VRE, 15 CRE) were included. Median age was 69 (range: 20-95), 18% were male, 14% were immunosuppressed and the median Charlson score was 4 (0-12). 33% had indwelling catheters and 10% of patients had neurogenic bladder. Increased frequency (29%) and fever (27%) were the most common symptoms. 51% of cases were healthcare associated and 64% met the CDC/NHSN definition of UTI. UTIs were complicated by pyelonephritis in 2 patients, but none had concomitant bacteremia. FOS was administered as empiric or definitive treatment in 39% and 61%, respectively. Only 12% of patients received >1 dose. Cure occurred in 88% of patients, and did not vary by infecting pathogen (Figure 1, Table 2 ), or the number of FOS doses received. Patients with relapsing symptoms were infected by ESBL (n = 3), CRE (n = 1), and VRE (n = 3); all but one received 1 dose of FOS. Microbiologic failures occurred in 18% due to ESBL (n = 1), CRE (n = 4), and VRE (n = 4). 4% of patients died in-hospital, but only 1 death was related to UTI. Overall, FOS was well-tolerated with vomiting recorded in one patient.
Conclusion. Across a range of MDR pathogens causing UTIs, FOS was well-tolerated and effective for hospitalized patients. FOS represents an attractive oral option to preserve alternative agents for systemic infections. Future studies are needed to evaluate the benefit of repeated dosing.
